Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy

Hepatocellular Carcinoma Clinical Trial

— SILIUS  

Official title:

Phase I/II Study of Sorafenib In Combination With Low-dose FP Intraarterial Infusion Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00933816
• Other study ID #: JLOG0901
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: July 1, 2009
• Last updated: November 24, 2010
• Start date: July 2009
• Est. completion date: October 2010

Study information

• Verified date: November 2010
• Source: Japan Liver Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the recommended dose of the combination therapy of sorafenib with hepatic arterial infusion of low dose cisplatin and fluorouracil on patients with advanced hepatocellular carcinoma (Phase I), and to evaluate the efficacy of this combination therapy in the recommended dose (Phase II).

Description:

In Phase I, there will be 9 to 18 patients enrolled. Cohorts of 3 to 6 patients will receive escalated dose of cisplatin and fluorouracil until the MTD is reached. There will be no intra-patient dose escalation. Sorafenib will be administered orally at a dose of 400mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330mg/m2 will be administered continuously at day1-day5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued. At the end of each cycle, adverse effect will be evaluated and dose escalation will be determined. In Phase II, there will be 28 patients enrolled. Time to progression of this combination therapy at the recommended dose will be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: October 2010
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. 20 Years and older.

2. Life expectancy of at least 12 weeks at the pre-treatment evaluation.

3. Advanced hepatocellular carcinoma with histological evidence on a biopsy specimen, or typical findings by dynamic CT or CT during hepatic arteriography/arterioportography.

4. Not suitable for resection or local ablation therapy or transcatheter arterial chemoembolization.

5. One treatment of hepatic arterial infusion chemotherapy without implanted catheter system is allowed.

6. ECOG Performance status of 0 or 1.

7. Cirrhotic status of Child-Pugh class A or B.

8. Adequate bone marrow, liver and renal function, as assessed by the following laboratory requirements:

• Hemoglobin 8.5 g/dl

• Granulocytes 1500/µL

• Platelet count 50,000 /µL

• PT-INR 2.3 or PT 6 seconds above control

• Total serum bilirubin 2 mg/dl

• AST(SGOT) and ALT(SGPT) 5 × upper limit of normal

• Serum creatinine 1.5 × upper limit of normal

• Amylase 5 × upper limit of normal

9. Written Informed Consent must be obtained.

Exclusion Criteria:

1. Previous malignancy (except for cervical carcinoma in situ, adequate treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis and T1], early gastric cancer, or other malignancies curatively treated > 3 years prior to entry

2. Renal failure

3. Any heart disease as follows

• Congestive heart failure defined as NYHA class III or IV

• Active coronary artery disease or ischemic heart disease such as cardiac infarction within 6 months prior to screening

• Serious cardiac arrhythmia

• Serious hypertension

4. Active clinically serious infections.

5. Active chicken pox.

6. Auditory disorder.

7. Known history of HIV infection.

8. Known metastatic or meningeal tumors.

9. Extrahepatic tumor spread.

10. History of seizure disorder.

11. Clinically significant gastrointestinal bleeding within 4 weeks prior to study entry.

12. Embolization or infarction such as transient ischemic disease, deep vein thrombosis, pulmonary embolization).

13. Any history of treatment as follows:

• Treatment with the agent which induces CYP3A4

• Surgical procedure within 4 weeks prior to start of study drug

• History of organ allograft

14. Patients unable to swallow oral medications.

15. Gastrointestinal disease that may affect to the absorption of drug or pharmacokinetics.

16. Medication that may affect to the absorption of drug or pharmacokinetics.

17. Any disease or disorder that may affect the evaluation of study drug.

18. Entry to the other clinical trial within 4 weeks prior to entry to this study.

19. Pregnant or breast-feeding patients.

20. Known allergy to the investigational agent or any agent given in association with this trial.

21. Substance abuse, medical, psychological or social conditions that, in the judgment of the investigator, is likely to interfere with the patient's participation in the study or evaluation of the stuy results.

22. Any condition that is unstable or could jeopardize the safety of the patient and its compliance in the study, in the investigator's judgment.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Drug:
• sorafenib, cisplatin, fluorouracil
Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.

Locations

Country	Name	City	State
Japan	Kurume University Medical Center	Kurume	Fukuoka
Japan	Ogaki Municipal Hospital	Oogaki	Gifu
Japan	Kinki University School of Medicine	Osaka-Sayama	Osaka

Sponsors (1)

Lead Sponsor	Collaborator
Japan Liver Oncology Group

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicity in phase I and Time to progression in Phase II		Every 4 weeks	Yes
Secondary	Phase I and II: Overall survival (OS)		Every day	Yes
Secondary	Phase I and II: Progression free survival (PFS)		Every four weeks	Yes
Secondary	Phase I: Time to progression (TTP)		Every four weeks	Yes
Secondary	Phase I and II: Response Rate (RR)		Every four weeks	Yes
Secondary	Phase I and II: Adverse effect (AE)		Every four weeks	Yes